Tae-Won Kim, PhD

Vice President, Toxicology Department at Ionis Pharmaceuticals

Speaker

Tae-Won Kim received his Ph.D. in Environmental and Molecular Toxicology from North Carolina State University in 1996, where his research focused on a mouse skin carcinogenesis model. He subsequently completed a postdoctoral fellowship at the University of California, San Francisco, specializing in tumor metastasis and oral carcinogenesis. Following his postdoctoral training, Dr. Kim joined SUGEN as a toxicologist in the Department of Pharmacokinetics and Toxicology, where he served as the Group Leader for the SUTENT program until 2001. He then joined Ionis Pharmaceuticals, formerly ISIS Pharmaceuticals. Dr. Kim currently serves as Vice President of Toxicology in Preclinical Development at Ionis Pharmaceuticals. In this role, he has led the nonclinical safety and toxicology development of seven approved therapies: mipomersen, inotersen, volanesorsen, eplontersen, olezarsen, donidalorsen, and zilganersen. He has also contributed to the submission of an additional NDA and oversees multiple antisense oligonucleotide and siRNA programs, including both conjugated and unconjugated compounds, across various stages of development.